Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
DULOXETINE (DULOXETINE HYDROCHLORIDE)
ANGITA PHARMA INC.
N06AX21
DULOXETINE
60MG
CAPSULE (DELAYED RELEASE)
DULOXETINE (DULOXETINE HYDROCHLORIDE) 60MG
ORAL
100
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0152350002; AHFS:
APPROVED
2018-05-04
______________________________________________________________________ AG-Duloxetine Product Monograph Page 1 of 82 PRODUCT MONOGRAPH Pr AG-Duloxetine Duloxetine Delayed-Release Capsules Duloxetine (as duloxetine hydrochloride) 30 mg and 60 mg Manufacturer’s standard Analgesic/Antidepressant/Anxiolytic Angita Pharma Inc. 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Submission Control No: 257576 Date of Revision: November 22, 2021 ______________________________________________________________________ AG-Duloxetine Product Monograph Page 2 of 82 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ........................................................................................................ 5 WARNINGS AND PRECAUTIONS ................................................................................. 6 ADVERSE REACTIONS .................................................................................................. 18 DRUG INTERACTIONS ................................................................................................. 37 DOSAGE AND ADMINISTRATION .............................................................................. 40 OVERDOSAGE ...................................................................................................................... 43 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 44 STORAGE AND STABILITY .......................................................................................... 47 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 47 PART II: SCIENTIFIC INFORMATION ................................................................................ 49 PHARMACEUTICAL INFORMATION .. Prečítajte si celý dokument